Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$168.59 USD

168.59
4,377,458

+2.03 (1.22%)

Updated Jun 14, 2024 04:00 PM ET

After-Market: $168.50 -0.09 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

The Zacks Analyst Blog Highlights: Boeing, AbbVie and U.S. Bancorp

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Boeing, AbbVie and U.S. Bancorp

    Can Novartis (NVS) Spring a Surprise This Earnings Season?

    by Zacks Equity Research

    Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report second-quarter 2017 results on Jul 18.

      Mark Vickery headshot

      Top Stock Reports for Boeing, AbbVie & U.S. Bancorp

      by Mark Vickery

      Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), AbbVie (ABBV), and U.S. Bancorp (USB).

        Amgen Gets FDA Nod to Broaden Leukemia Drug Blincyto's Label

        by Zacks Equity Research

        Amgen Inc. (AMGN) announced that its supplemental biologics license application (sBLA) to convert accelerated approval for leukemia drug Blincyto to regular approval has been approved by the FDA.

          Sweta Killa headshot

          IPO Market Back On Track: ETFs to Tap

          by Sweta Killa

          After several lackluster quarters, the U.S. IPO market gained momentum in the second quarter of 2017.

            Roche (RHHBY) Announces Positive Data on Hemophilia A Drug

            by Zacks Equity Research

            Roche Holdings AG (RHHBY) announced positive data from the phase III study, HAVEN 1, on hemophilia A candidate emicizumab.

              Novartis' Cosentyx Superior to Stelara in Psoriasis Study

              by Zacks Equity Research

              Novartis' (NVS) psoriasis drug Cosentyx got a label update from the Committee for Medicinal Products for Human Use (CHMP) in the EU,

                Bristol-Myers Gets FDA Nod for Orencia's Label Expansion

                by Zacks Equity Research

                Bristol-Myers Squibb Company (BMY) announced that the FDA has approved Orencia for treatment of adults with active psoriatic arthritis (PsA).

                  Galapagos-Gilead Begin Phase II Study on Uveitis Candidate

                  by Zacks Equity Research

                  Galapagos NV (GLPG) has announced initiation of a new phase II study, evaluating its lead pipeline candidate filgotinib for treatment of adult patients with non-infectious uveitis.

                    Bayer Starts Phase III Study for Uterine Fibroids' Candidate

                    by Zacks Equity Research

                    Bayer Aktiengesellschaft (BAYRY) announced that it has enrolled the first patient in a phase III study ASTEROID which will evaluate vilaprisan in women suffering from uterine fibroids.

                      Roche's (RHHBY) Leukemia Drug Gets Prime Status in EU

                      by Zacks Equity Research

                      Roche (RHHBY) announced that its investigational drug polatuzumab vedot in combination with MabThera and bendamustine was granted prime status in the EU.

                        Arpita Dutt headshot

                        Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod

                        by Arpita Dutt

                        Key highlights in the biotech sector include FDA approval for Portola's (PTLA) anticoagulant and EU approval for Regeneron's rheumatoid arthritis (RA) drug.

                          Gilead's (GILD) HCV Drug Application Accepted in the EU

                          by Zacks Equity Research

                          Gilead Sciences, Inc. (GILD) announced that the CHMP has adopted a positive opinion on the company's application for HCV drug Vosevi.

                            Bristol-Myers Reports Data on Immuno-Oncology Drug Empliciti

                            by Zacks Equity Research

                            Bristol-Myers Squibb Company (BMY) announced four-year follow-up data from the phase III study, ELOQUENT-2 on immuno-oncology Empliciti.

                              AbbVie's HCV Combo Drug Gets Positive CHMP Opinion in EU

                              by Zacks Equity Research

                              AbbVie Inc. (ABBV) announced that the CHMP of the EMA has recommended marketing approval of its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P).

                                Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU

                                by Zacks Equity Research

                                Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Commission has granted marketing approval to its rheumatoid arthritis (RA) drug Kevzara.

                                  J&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study

                                  by Zacks Equity Research

                                  Johnson & Johnson (JNJ) announced a three-year follow-up data from a late stage study, evaluating its cancer drug Imbruvica against Pfizer's Torisel for treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).

                                    AbbVie (ABBV) Stock Hits 52-Week High: More Room to Run?

                                    by Zacks Equity Research

                                    AbbVie Inc. (ABBV) shares hit a 52-week high of $71.12 on Friday before eventually closing at $71.05.

                                      Novartis (NVS) Announced Positive Data on Psoriasis Cosentyx

                                      by Zacks Equity Research

                                      Novartis AG (NVS) announced positive data on arthritis drug Cosentyx from two phase III studies.

                                        Arpita Dutt headshot

                                        Biotech Stock Roundup: Management Changes at Biogen, Alexion, GILD Files HIV Drug

                                        by Arpita Dutt

                                        Key highlights in the biotech sector include management changes for Biogen (BIIB) and Alexion as well as a regulatory filing for Gilead's HIV regimen.

                                          AbbVie (ABBV) Announced Positive Phase III RA Candidate Data

                                          by Zacks Equity Research

                                          AbbVie Inc. (ABBV) announced positive top-line results from a phase III study on rheumatoid arthritis candidate, upadacitinib (ABT-494).

                                            Novartis Biosimilar Pipeline, 2018 Growth Plans on Track

                                            by Zacks Equity Research

                                            Novartis AG (NVS) announced that the EMA has accepted its applications for biosimilar versions of AbbVie's (ABBV) Humira (adalimumab) and Johnson & Johnson's (JNJ) Remicade (infliximab) for review.

                                              Arpita Dutt headshot

                                              Biotech Stock Roundup: Puma Soars on Advisory Panel Vote, Priority Review for Kite Drug

                                              by Arpita Dutt

                                              Key highlights in the biotech sector include a favorable advisory panel vote for Puma (PBYI) and positive data and positive data from companies like Inovio and BioCryst.

                                                Biogen's Fampyra Conditional Approval Converted to Standard

                                                by Zacks Equity Research

                                                Biogen Inc. (BIIB) announced that the conditional marketing authorization for its drug Fampyra for improvement of walking in multiple sclerosis (MS) patients in the EU has been converted to a standard marketing approval.

                                                  The Zacks Analyst Blog Highlights: Boeing, AbbVie, UnitedHealth, Consolidated Edison and Cisco

                                                  by Zacks Equity Research

                                                  The Zacks Analyst Blog Highlights: Boeing, AbbVie, UnitedHealth, Consolidated Edison and Cisco